With Wegovy and Zepbound shortages officially over, I wondered what was going on with the cheaper compounded alternatives that so many patients I've spoken with have relied on. My latest for @npr.org with some fresh data and lots of context: www.npr.org/sections/sho...

Hi! If you need to reach me confidentially, here's how:

New from me at @npr.org: Patients are scrambling as cheaper alternatives to Eli Lilly's blockbuster obesity drug Zepbound disappear. Today is the deadline for compounding pharmacies to stop making tirzepatide.